Nevro Acquisition Finalized as Trading Ceases on NYSE

The independent public trading journey of Nevro has reached its conclusion. Effective April 3, 2025, the company’s shares are no longer listed on the New York Stock Exchange, following its complete acquisition by Globus Medical.

A $250 Million Transaction Seals the Deal

The acquisition process, which was initially announced in February 2025, was finalized this April. The transaction saw Globus Medical disburse approximately $250 million in cash and assume all of Nevro’s outstanding shares. Shareholders received $5.85 for each share they held. The agreement received unanimous approval from the boards of directors of both corporations.

With the deal’s completion, Nevro now operates as a wholly-owned subsidiary of Globus Medical. Trading of Nevro stock was terminated immediately, and its NYSE listing was revoked. Furthermore, Nevro’s outstanding convertible debt was fully repaid in early April 2025.

Final Financial Disclosures Reveal Challenges

Prior to the takeover, Nevro released its financial results for the full year 2024, presenting a difficult financial picture:
* Global revenue reached $408.5 million, reflecting a 3.9% decline compared to 2023.
* The company reported a net operating loss of $126.2 million.
* No financial guidance for 2025 was provided, citing the pending acquisition.

Should investors sell immediately? Or is it worth buying Nevro?

This period of underwhelming performance positioned the company for acquisition by its larger competitor. A key question now is what the integration means for Nevro’s technological assets.

Neurostimulation Assets Change Hands

Through this acquisition, Globus Medical gains control of Nevro’s portfolio of innovative neurostimulation technologies. This includes the HFX platform for spinal cord stimulation, which encompasses several key systems:
* A proprietary 10-kHz therapy designed for paresthesia-free pain relief.
* The HFX-iQ system, powered by the HFX-AdaptivAI platform.
* Various technologies aimed at treating chronic pain of the trunk and limbs.

The AI-supported platform, launched in November 2024, represents a significant step in personalized pain therapy by automatically adjusting stimulation parameters based on patient feedback.

For investors who maintain an interest in the future of these technologies, the path forward is clear: attention must now shift to the reports and announcements issued by Globus Medical, which will henceforth communicate the performance and integration of the acquired assets.